Clinical Trial Update: Extension Study to Assess the Long-Term Safety of Tegaserod in Women With Symptoms of Dyspepsia [Phase 3]

View source ↗

Summary

Extension study to assess the long-term safety of tegaserod in women with symptoms of dyspepsia (Phase 3) sponsored by Novartis; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyspepsia

Drugs mentioned

• Tegaserod (tegaserod)

Snippet

Sponsor: Novartis | Conditions: Dyspepsia | Phase 3 | Status: COMPLETED